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Cognitive impairment creates significant challenges for patients, their families and friends, and 
clinicians who provide their health care. Early recognition allows for diagnosis and appropriate 
treatment, education, psychosocial support, and engagement in shared decision-making regarding 
life planning, health care, involvement in research, and financial matters. An IAGG-GARN 
consensus panel examined the importance of early recognition of impaired cognitive health. Their 
major conclusion was that case-finding by physicians and health professionals is an important step 
toward enhancing brain health for aging populations throughout the world. This conclusion is in 
keeping with the position of the United States’ Centers for Medicare and Medicaid Services that 
reimburses for detection of cognitive impairment as part the of Medicare Annual Wellness Visit 
and with the international call for early detection of cognitive impairment as a patient’s right. The 
panel agreed on the following specific findings: (1) validated screening tests are available that take 
3 to 7 minutes to administer; (2) a combination of patient- and informant-based screens is the most 
appropriate approach for identifying early cognitive impairment; (3) early cognitive impairment 
may have treatable components; and (4) emerging data support a combination of medical and 
lifestyle interventions as a potential way to delay or reduce cognitive decline.
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Cognition (the ability to learn, solve problems, remember, and appropriately use stored 
information) is a key to successful health and aging. A variety of conditions, many age-
associated, adversely affect cognition. After the age of 70, numerous studies suggest that 
approximately 16% of persons have mild cognitive impairment (MCI) and 14% experience 
dementia.1–5 Approximately two-thirds of persons with dementia identified in population 
studies have Alzheimer disease (AD), either alone or in combination with other diseases.5–9 
Because of the importance of the maintenance of cognitive health or brain health to both the 
individual and society, the International Association of Gerontology and Geriatrics (IAGG) 
and its Global Aging Research Network (GARN) convened an expert consensus panel to (1) 
determine the role of screening and/or case-finding to identify early cognitive impairment, 
(2) establish the minimum workup/advice that providers should give to a person with early 
cognitive impairment, (3) explore if the management of persons with subjective cognitive 
impairment should differ from that of persons with objective cognitive impairment, and (4) 
decide if cognitive frailty (a mixture of both mental and physical frailty) is a useful concept 
for research and clinical care.10–12
An expert panel (referred to hereafter as “panel”), including neurologists, psychiatrists, 
geriatricians, social workers, and psychologists, was convened in St Louis, MO, in March 
2015. The methodology followed a modified Delphi approach, which has been used 
previously to obtain consensus.13,14 Before the conference, the panelists were surveyed 
using a series of questions pertinent to the objectives. During the panel meeting, the results 
of the survey were made available to the participants, along with results of focus groups of 
persons with dementia (n = 6), care partners (n = 8), and staff and volunteers (n = 9). The 
panel discussed in detail several key areas: Preferred terminology for early cognitive 
impairment; the distinction between screening and case-finding; screening instruments; post-
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screening recommendations, including the role of antidementia drugs and treatment of 
potentially remediable components of cognitive impairment, possible nutritional and 
exercise (physical and cognitive) interventions, and utility of biomarkers for etiological 
diagnosis; the interaction between physical and cognitive failure; and possible next steps. A 
draft manuscript was then developed, circulated, and revised until the panelists arrived at 
consensus on the content.
Cognition is a Key to Good Health
Cognitive impairment is recognized as being either syndromic (eg, MCI, subjective 
cognitive decline, mild neurocognitive disorder, or cognitive frailty) or etiologic (eg, 
prodromal AD or early symptomatic AD).15 The premeeting survey results identified that 
60% of participants favored MCI as the term of choice, but panel members recognized the 
importance of framing the issue in the more positive terms of “cognitive (brain) health” to 
reduce public fears that may impede early detection and to encourage positive steps toward 
preserving cognitive function throughout the life course.
A stimulus in the United States toward providing guidelines relative to the recognition and 
management of cognitive health is the creation of a new Medicare benefit, the Annual 
Wellness Visit (AWV), under the Patient Protection and Affordable Care Act of 2010.16 
Among the reimbursable components of the AWV is detection of any cognitive impairment. 
In a 1996 study, physicians at the Mayo Clinic in Minnesota found the Mini-Mental State 
Examination (MMSE),17 in 4000 persons 60 to 102 years of age to be of little value from the 
physician’s point of view.18 On the other hand, in southern France, family practitioners have 
found a very brief screen for memory problems and physical frailty to be highly useful to 
determine need for specialist referral when coupled with the ability to refer patients to a 
specialty clinic for further evaluation.19 Screening for cognitive impairment has been carried 
out in primary care and community settings.20–23
Cognitive impairment and dementia, when present, are either not recognized or recognized 
and not documented, in more than half of patients seen by primary care physicians.24–28 The 
US Preventive Services Task Force, using a systematic review, determined that, “there is no 
empirical evidence that screening improves decision making.”29 We note that this 
conclusion was based on limited studies reporting health outcomes in persons with 
dementia. The Gerontological Society of America (GSA) has issued a report providing 9 
potential benefits of early diagnosis of dementia (https://www.geron.org/images/gsa/
documents/gsaciworkgroup2015report.pdf). The GSA report also provided a 4-step 
approach to the diagnosis and management for detection of cognitive impairment and/or 
dementia, while recognizing that the approach still requires validation.
The panel recognized the important public health distinction between screening and case-
finding. By definition, screening is universal and involves a brief assessment of all 
individuals within a certain category (for example, all of a certain age). It is well-established 
that the strongest risk factor for AD and other dementias is age.30 Although the panel was 
split on whether universal screening should be carried out, many members supported 70 
years as an appropriate age threshold for screening. The focus groups (persons with 
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dementia, care partners, and direct practice staff and volunteers) were generally supportive 
of universal screening with several caveats, including the need for standardization of 
screening tools and adequate training for the provider administering the screening tool. 
Interestingly, the focus groups believed that screening at age 70 years was too late and 
advocated for earlier (by age 55 years) screening. In contrast to screening, case-finding is the 
assessment of a subgroup of individuals identified on the basis of known risk factors (eg, 
subjective cognitive concerns or family history of dementia) to be carried out by physicians 
and other health professionals. Table 1 depicts the way in which screening for cognitive 
impairment and dementia might fulfill the World Health Organization (Wilson’s criteria) 
guidelines for screening.
The IAGG panel strongly endorses the viewpoint that international studies must determine 
the most cost-effective approach to identification and management of cognitive impairment 
in different settings and populations. However, like the GSA, the panel determined that, at a 
minimum, case-finding by physicians and other health professionals is important to enhance 
brain health throughout the world.
Screening Instruments
More than half of the panelists believe that an ideal screening instrument should be less than 
5 minutes, although 5 to 7 minutes for screening was also considered reasonable. A number 
of validated screening instruments are available (Table 2). Of these, the Ascertain Dementia 
8 (AD8) is an informant-based screening tool, which also may be useful in patients with 
MCI.31–34 The items in the AD8 address memory, temporal orientation, judgment, and 
function. It has a sensitivity of 85% and specificity of 92%. Informant report has a better 
association with disease than self-rated report.35 The AD8 has been validated in Korea, 
Brazil, Spain, Japan, China, and Taiwan.36–41
A number of objective screening tests are available. The MiniCog meets the criterion of 
taking less than 3 minutes to administer.42–45 The Rapid Cognitive Screen (RCS), developed 
from the Saint Louis University Mental Status (SLUMS) examination, also takes less than 3 
minutes and validations are available in 2 studies.46 SLUMS has excellent receiver operating 
curves to distinguish both MCI and dementia. From an international perspective, the 
SLUMS is available in 24 languages (http://aging.slu.edu/index.php?page=saint-louis-
university-mental-status-slums-exam).47–49 “The 5-word test” has been validated in AD 
(specificity 87%). It has a positive predictive value of 83% and a negative predictive value of 
93%.50 It takes 2 minutes to administer and is widely used in France. The panel agreed that 
all of these tools, as well as others, were acceptable for screening and selection should be 
left to the discretion of the provider.
Figure 1 illustrates that screening implementation requires a variety of components to allow 
for successful administration. These include training of the physicians and other health care 
professionals who administer the instrument, appropriate preparation of the patient/
informant, immediate follow-up, and later follow-up.
Screening is typically accomplished by a simple test with a single score at a single point in 
time, to identify those patients who deserve a more complete diagnostic assessment by an 
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expert clinician. An individual’s performance at a single point in time provides no 
information about the course of his or her cognitive functioning over time. The diagnosis of 
the progressive dementias, such as probable AD, depends on the patient experiencing 
cognitive decline over time. At the initial assessment, this information is typically obtained 
from the history. Ideally, decline should be identified based on serial objective assessments 
(repeated cognitive testing) over time (Figure 2). By using a well-validated cognitive test 
with established normative values for a range of age and educational groups, the clinician 
can compare a given patient’s actual performance on the test, even on a single occasion, with 
the expected values for an individual of the same age and education. Test performance below 
the expected range strongly suggests that decline has occurred.
An example of an optimal, 2-pronged, approach to assessment might include administering 
an objective test to the patient, while the care partner or informant completes a questionnaire 
such as the AD8. Overall an “ideal” screening tool should be brief, have no copyrighted 
costs, and be able to be administered by any appropriately trained individual. There are 
limitations of many screening instruments in low education/illiterate populations. In 
addition, there is a need for culturally fair instruments.
The use of biomarkers (Table 3) for etiological diagnosis furthers our understanding of 
disease trajectories, but should be limited to use by specialists after an extensive clinical 
evaluation.51–55 This emerging area of interest has led to different opinions from the 
National Institute on Aging/Alzheimer’s Association and the International Working Group 
as to the role of biomarkers in the clinical evaluation of the patient.56–58
Potential Benefits of Early Diagnosis of Cognitive Impairment
When screening or case-finding reveals cognitive impairment, the health care professional 
can take the appropriate steps toward diagnosis and treatment. When testing fails to find 
cognitive impairment, this reassurance allows persons to re-focus on enjoying their “brain 
health.” A negative screen may bring relief to older persons who fear that their normal age-
related cognitive changes represent the beginnings of AD.
Whether or not the screening information is shared with the patient and family, physicians 
and other health professionals should know that their patient is cognitively impaired. 
Management of chronic medical conditions requires the patient to enter into an active 
partnership with his or her health care professionals to obtain the best outcome. Besides 
failing to take their medications, cognitively impaired patients often fail to carry out other 
simple instructions from their physicians. These patients may not understand the explanation 
of their disease given to them by their physician or its implications. The same may be true of 
family members who are present when the diagnosis is given.59 Therefore, the clinician 
delivering the diagnosis should check for comprehension in both the patient and family 
members.
There also are numerous potentially reversible causes of cognitive impairment, including 
some which are clearly treatable when diagnosed early. These include anticholinergic 
medications,60–62 polypharmacy,63,64 depression,65 metabolic disorders such as 
hypothyroidism and hypercalcemia,66 normal-pressure hydrocephalus,67 space-occupying 
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lesions in the brain, infections, and sleep apnea.68,69 Defects in vision and hearing can lead 
to poor performance on cognitive screening and prolonged sensory isolation can result in 
cognitive impairment.62
Patients with white matter hyperintensities on magnetic resonance imaging (MRI), 
suggestive of ischemic brain damage, may have treatable conditions that when controlled 
could slow down further ischemic brain damage and possibly the development of AD.70–73 
These include hypertension, diabetes, hyperlipidemia, smoking, and atrial fibrillation.74–76 
Both heart failure and chronic obstructive pulmonary disease are associated with an 
increased risk of cognitive impairment.77,78 This suggests early treatment and improvement 
of oxygenation may slow the development of cognitive impairment.
Persons with diabetes mellitus have early onset of cognitive impairment and a higher 
likelihood of developing dementia.79–81 Hyperglycemia has been associated with reversible 
cognitive impairment in humans and animals.82–84
There are a number of lifestyle changes that have reasonable evidence for slowing down the 
rate of cognitive deterioration. Epidemiological studies support that persons consuming 
Mediterranean-style diets are less likely to have cognitive impairment.85–87 In addition, the 
PREDIMED-NAVARRA study showed that a Mediterranean diet slowed the development of 
cognitive impairment after 6.5 years compared with a low-fat diet.88 Extravirgin olive oil 
improves memory and reduces oxidative damage in the SAMP8 mouse89 and extra-virgin 
olive oil was slightly better than nuts in improving cognition in the PREDIMED-NAVARRA 
study.90 Mediterranean diet characteristics include fruit and vegetables, fish 2 times a week, 
olive oil, nuts, legumes, and whole grains. The “MIND-diet,” which incorporates elements 
of both the Mediterranean diet and the “DASH diet,” has been linked with a lower risk of 
cognitive impairment91 and the development of AD.92 It is recognized that association in 
epidemiological studies does not prove causality. The FINGER and PREDIMED-
NAVARRA studies were controlled interventional studies, helping to confirm causality.
Although epidemiological studies have found that foods rich in antioxidant vitamins reduce 
the risk of AD,93 intervention studies with antioxidant vitamins have been 
disappointing,94,95 although 2000 IU per day of vitamin E did result in a slight, but 
significantly less, decline in the Alzheimer’s Disease Co-operative Study/Activities of Daily 
Living Inventory.96 Similarly, supplementation with B-vitamin supplements has not been 
effective except in cases of clear vitamin B deficiency or in countries where bread is not 
fortified with folate.94,97–100 Preclinical studies have shown that a combination of nutrients 
involved in the Kennedy pathway for biosynthesis of neuronal membranes (including uridine 
monophosphate, choline and phospholipids) increased surrogate markers for synapse 
formation. In addition, in vivo studies showed that dietary enrichment with these nutrients 
improved neurotransmission, learning, and memory.101 It has been shown that patients with 
AD may be partially deficient in some of these essential nutrients.102 This led to the 
development of a specific nutrient combination (Souvenaid), which has been tested in 
humans. Although the results were negative in persons with established dementia, 
improvement in immediate and delayed verbal memory was seen in early cognitive 
dysfunction103,104 and was sustained over a 12-month period without any safety issues being 
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observed. A European Union–funded trial (Lipidiet Consortium) is examining the effects in 
persons with prodromal AD. Medium-chain triglycerides (Axona), which are metabolized to 
ketone bodies, have been shown to have a small effect on memory in APOE4-negative 
individuals, but more studies are needed.105,106 Overall, the consensus group concluded that 
a Mediterranean-type diet is a reasonable recommendation for persons with early cognitive 
dysfunction, whereas further evidence in early AD or MCI is awaited. Further studies are 
necessary to provide evidence for the efficacy for special dietary formulations.
An analysis of population-based data found that the population attributable risk for AD in 
the United States, Europe, and the United Kingdom was highest for physical inactivity.107 A 
meta-analysis of prospective studies in persons without dementia (n = 33,816) found that 
physical exercise was protective against cognitive decline.108 The Cochrane meta-analysis 
suggested physical exercise had effects on delayed memory functions and auditory 
attention.109 Another meta-analysis involving 14 randomized controlled trials (RCTs) found 
exercise had a very small significant effect on improving verbal fluency and no other 
significant effects.110 Wang et al111 found an effect of exercise on global cognitive function. 
Many of these studies were conducted over relatively short periods. A year-long aerobic 
exercise training study in older adults improved memory and hippocampal volume.112 
However, in another smaller study, the investigators failed to show an effect on cognition 
over a year.113 In a study of resistance training in persons with MCI, there was a significant 
improvement in global cognitive function and maintenance of executive function over 18 
months.114 In the Fitness for Aging Brain study, physical activity enhanced cognitive scores, 
compared with an educational program over the 18-month follow-up.115 A meta-analysis of 
2533 participants found that Tai Chi enhanced both executive function and global cognitive 
function.116 This was reinforced by a recent study.117 Despite strong epidemiological 
evidence for a relationship between physical fitness and cognition,118 the intervention 
studies have not shown large effects and none has shown protection against markers of 
neurodegenerative diseases, including AD. Moreover, none of the studies showed that the 
positive cognitive effects translated to everyday life; that is, the effects were not clinically 
meaningful. As physical exercise has many benefits for older persons and is generally 
recommended, the panel endorsed this recommendation for persons with cognitive 
impairment.
Epidemiologically, there is less cognitive decline in persons who have higher levels of 
engagement in intellectual activity, play a musical instrument, or dance.119–122 The 
Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) study provided 
cognitive exercises once a week for 10 weeks in 2832 older persons.122 Participants in this 
intervention showed improvement in memory, reasoning, and processing even after 5 years 
of follow-up, although transfer of cognitive training benefits to improvements in real-world 
activities remains to be established.123 In persons with mild to moderate dementia, cognitive 
stimulation therapy (CST) has been shown to improve cognition.124–130 CST also improves 
quality of life and is at least as effective as cholinesterase inhibitors in persons with 
dementia.131 Reminiscence therapy has been shown to have a small effect on cognition and 
possibly quality of life.132–135 Combinations of cognitive and exercise training can enhance 
cognitive function and functional status in older adults, but more studies are needed.132
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Video game training produces positive effects on global cognition, memory, reaction time, 
and attention in older adults.136,137
The Agency for Healthcare Research and Quality produced a meta-analysis examining 
factors associated with cognitive decline.29 Overall, the evidence suggested that physical and 
cognitive activities were associated with lesser cognitive decline in aging. However, there is 
no evidence for a causal relationship, and the National Institute on Aging State-of-the-
Science Conference could not make confident recommendations for preserving cognitive 
health based on existing evidence.138
Given that cognitive impairment and dementia/AD are multifactorial disorders, targeting 
several risk factors simultaneously may be needed for optimal preventive effect.139 The 
Finnish geriatric intervention study to prevent cognitive impairment and disability 
(FINGER)140 is the first large, long-term RCT showing that multidomain lifestyle-based 
intervention can maintain cognitive function and reduce cognitive decline in older at-risk 
individuals. In this study, 1260 persons aged 60 to 77 years were included and screened 
based on the Dementia Risk Score.141 Half were randomly allocated to the multidomain 
intervention group (consisting of physical exercise, healthy diet, cognitive diet, and vascular 
risk monitoring), and half were allocated to a control group that received regular health 
advice only. After 2 years, the intervention group had significantly better 
Neuropsychological Test Battery score (primary outcome) and lower risk for cognitive 
decline compared with the controls.140 Extended follow-up (up to 7 years) is ongoing to 
determine the effect on incidence of dementia and AD, other health outcomes, and long-term 
adherence to lifestyle intervention.
There are 2 other large, multidomain RCTs in Europe aiming to prevent cognitive 
impairment and dementia: The MAPT trial in France, and the pre-DIVA study in the 
Netherlands.139 Both of these trials have been recently finalized and results are awaited. 
Research groups from these 3 trials (FINGER, MAPT, pre-DIVA) have established 
European Dementia Prevention Initiative (EDPI; www.edpi.org) aiming to better use the 
available data. Through combined data analyses (totaling >6000 participants) and sharing of 
experiences about methodological issues, EDPI aims to improve multidomain preventive 
strategies that can be tested in larger studies.
The IAGG panelists recognized the paucity of high-quality randomized trials to make 
recommendations, but were in general agreement that positive lifestyle changes, such as 
those embodied in FINGER, should be recommended to all persons with early cognitive 
impairment.
Cholinesterase inhibitors do not improve cognition in persons with MCI (with the possible 
exception of prodromal AD).142 Memantine should not be used in early AD.
Cognitive impairment at any level of severity creates significant challenges for both 
individuals and family members.143 Early recognition sets the stage for ongoing engagement 
of patients, family members, and clinicians in person-centered, individualized partnerships 
to optimize both medical and psychosocial outcomes over time. Early recognition of 
cognitive impairment allows the person to reprioritize personal life goals, and to develop 
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advanced directives for health, legal, and financial matters that fit with their preferences. 
This also allows the person to work with his or her family to identify and avoid major 
potential risks (eg, susceptibility to theft; wandering; unsafe use of tools, appliances, and 
guns; and operating motor vehicles). Early recognition also allows education for the person 
and the family on the effects of cognitive impairment and to engage both in activities that 
mitigate stress. Finally, early detection gives individuals the opportunity to make their own 
informed decisions about participation in research.
The recommendations that health care professionals should provide to persons with 
cognitive impairment are outlined in Table 4.
Cognitive Frailty
Cognitive frailty is a term that has recently emerged in the geriatrics literature inspired by 
potential parallel links to and possible common underlying mechanisms with the physical 
frailty syndrome. Physical frailty has been defined as “a medical syndrome with multiple 
causes and contributors that is characterized by diminished strength, endurance, and reduced 
physiologic function that increases an individual’s vulnerability for developing increased 
dependency and/or death.”14 Recently it has been recognized that a subgroup of persons 
with cognitive impairment have reduced resilience and functional decline that interacts with 
physical frailty. Converging evidence suggests that the cognitive status represents an 
important dimension of the frailty syndrome. Epidemiological studies have shown an 
association between frailty and late-life cognitive decline, incident MCI and AD, and non-
AD dementias.144 It has been suggested that cognitive frailty can be defined as a reduced 
cognitive function (clinical dementia rating score = 0.5) with the cognitive impairment being 
due to either physical or brain disease,29,145 or accelerated brain aging in the absence of 
evident brain disease. Physical frailty has to coexist to evoke the term cognitive frailty. It 
manifests commonly with executive dysfunction (frontal cortex) and less with pure amnestic 
defects (mesial temporal cortex). Others have suggested that the deficits in frail and prefrail 
patients in executive function and memory may be similar in size.146
There is some evidence that, even with normal aging, both cognitive decline and physical 
frailty often coexist.147–149 Cross-sectional studies find a high level of coexistence between 
rates of cognitive impairment and dementia and physical frailty.150 Frailty predicts cognitive 
decline and incident dementia,151,152 and cognitive impairment predicts frailty153,154 in 
longitudinal studies. Loss of executive function and poor attention are particularly associated 
with slow gait.155 There is increasing evidence that persons with white matter 
hyperintensities have poor balance, poor get up and go performance, slow gait speed, and 
increased falls.156–158 White matter hyperintensities also predict functional decline.159
The panelists agreed that persons with cognitive decline should be screened for physical 
frailty and vice versa. Although the concept of cognitive frailty may eventually yield useful 
insights and expanded predictability of function and disease outcomes, the panelists, 
however, considered it premature to incorporate cognitive frailty into the diagnostic lexicon 
and agreed that more studies on the interaction of the 2 entities and their pathophysiology 
are needed.
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Conclusion
There was consensus that all persons 70 years and older should have their cognitive function 
(subjectively and objectively) evaluated when visiting their health care provider, at least 
once a year. The objectives of this assessment are to identify treatable disease, provide 
lifestyle guidance to try to slow cognitive impairment, to allow recognition of patients who 
may struggle understanding a physician’s instructions, and to allow patients and their 
families to adequately prepare if they are at risk for developing dementia. Although this will 
vary by setting and circumstance, it was agreed that screening instruments should take less 
than 3 to 7 minutes to administer. The need to follow an individual longitudinally (ie, serial 
assessments) to demonstrate a deterioration in his or her performance was considered an 
important component of case-finding. The concept of cognitive frailty was viewed as being 
of interest but needs further research and development. The panel supports the Institute of 
Medicine’s Report Brief that there is a need for a greater societal commitment to promote 
cognitive health (http://www.iom.edu/reports/2015/cognitive-aging.aspx). It is suggested that 
when communicating with the public, the term “cognitive (brain) health” may be more 
acceptable than talking about cognitive impairment or dementia.
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Fig. 1. 
Process for implementing screening.
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Fig. 2. 
Schematic demonstrating the importance of intra-individual change in confirming the 
diagnosis.
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Table 1
Application of the World Health Organization (Wilson’s Criteria) Screening Criteria to Cognitive Impairment 
and Dementia
Cognitive Impairment Dementia
1 The condition should be an important health problem YES YES
2 There should be treatment for the condition Some Slow Deterioration
3 Facilities for diagnosis and treatment should be available Some Some
4 There should be a latent stage of disease Uncertain YES
5 There should be a test or examination for the condition YES YES
6 The test should be acceptable to the population YES YES
7 The natural history of the disease should be adequately understood Possibly YES
8 There should be an agreed on policy of who to treat Possibly YES
9 The total cost of finding a case should be economically balanced YES YES
10 Case-finding should be a continuous process, not just a “once-and-for-all project” YES YES
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Table 3
Potential Biomarkers for Persons With Cognitive Impairment
Biomarker Utility
MRI Ischemic disease (white matter hyperintensities), normal-pressure hydrocephalus, space-occupying 
lesions, vasculitis; AD (hippocampal volume, cortical thinning)
Cerebral spinal fluid Amyloid β and Tau AD
Positron emission tomography
Fluorodeoxyglucose AD/Lewy body dementia
Pittsburgh compound β AD
Florbetapir AD
Florbetaben AD; frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDR-17)
Tau
Single-photon emission computerized tomography
  Dopamine transporter Lewy body dementia
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Table 4
Recommendations for the Management of Early Cognitive Impairment
• Spend enough time with the patient and, when appropriate, family members, to ensure maximum understanding of the condition and 
recommended care. Provide written instructions. When necessary, engage a care partner to help carry out recommendations.
• Identify all potentially reversible causes of cognitive impairment.
• Provide advice regarding lifestyle practices and follow-up on implementation:
i. The Mediterranean or similar diet including olive oil
ii. Physical exercise
iii. Intellectual activities
iv. CST for persons with early or moderate AD
• Discuss the potential use of cholinesterase inhibitors in persons with AD
• Encourage the person to develop advanced directives for health, legal, and financial matters, and follow-up on whether this was 
done
• Educate the patient and family through recognized specialty organizations (eg, the Alzheimer’s Association in the US)
• Address, and take steps to avoid, major risks associated with cognitive impairment (eg, money management, “safe return” bracelet, 
appropriate disposition of unsafe tools and guns, driving)
• Encourage identification and use of support services (eg, support groups, family and friend engagement activities)
• Talk about potential research participation and help the person to make his or her own informed decisions
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